91 related articles for article (PubMed ID: 25109)
1. Mechanisms of Parkinson's disease.
Br Med J; 1978 Apr; 1(6117):872-3. PubMed ID: 25109
[No Abstract] [Full Text] [Related]
2. [Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects].
Korf J; van Praagen HM; Lakke JP
Ned Tijdschr Geneeskd; 1975 Sep; 119(36):1373-8. PubMed ID: 241026
[No Abstract] [Full Text] [Related]
3. [Parkinson disease and the neuronal dopamine uptake complex].
Costentin J
Ann Pharm Fr; 1995; 53(4):145-54. PubMed ID: 7574268
[TBL] [Abstract][Full Text] [Related]
4. [Problems and future perspectives in the treatment of Parkinson's disease].
Hens L; Hellemans J
Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease and dementia.
Agid Y; Ruberg M; Dubois B; Pillon B; Cusimano G; Raisman R; Cash R; Lhermitte F; Javoy-Agid F
Clin Neuropharmacol; 1986; 9 Suppl 2():S22-36. PubMed ID: 2885087
[No Abstract] [Full Text] [Related]
6. Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz O; Kish SJ
Adv Neurol; 1987; 45():19-34. PubMed ID: 2881444
[No Abstract] [Full Text] [Related]
7. Transmitter receptor alterations in Parkinson's disease.
Calne DB; Stoessl AJ
Adv Neurol; 1987; 45():45-9. PubMed ID: 2881449
[No Abstract] [Full Text] [Related]
8. [Biological psychiatry. 1) The dopamine-acetylcholine equilibrium model].
Adèr JP
TVZ; 1988 Jan; 42(1):13-6. PubMed ID: 2895504
[No Abstract] [Full Text] [Related]
9. Neurotransmitters and neurodegenerative disorders.
Kanazawa I
Clin Ther; 1984; 7 Spec No():48-58. PubMed ID: 6152198
[TBL] [Abstract][Full Text] [Related]
10. Effect of phenothiazines on dopamine metabolism and biochemistry of Parkinson's disease.
Barbeau A
Agressologie; 1968; 9(2):195-200. PubMed ID: 5675486
[No Abstract] [Full Text] [Related]
11. Neurotoxicity and the mechanisms of cell death in Parkinson's disease.
Schapira AH
Adv Neurol; 1996; 69():161-5. PubMed ID: 8615125
[No Abstract] [Full Text] [Related]
12. The probenecid test.
Korczyn AD
J Neural Transm Suppl; 1983; 19():173-83. PubMed ID: 6142088
[TBL] [Abstract][Full Text] [Related]
13. Potential nondopaminergic drugs for Parkinson's disease.
Silverdale MA; Fox SH; Crossman AR; Brotchie JM
Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
[No Abstract] [Full Text] [Related]
14. Developments in the pharmacology and therapeutics of parkinsonism.
Calne DB
Ann Neurol; 1977 Feb; 1(2):111-9. PubMed ID: 18978
[No Abstract] [Full Text] [Related]
15. Nondopaminergic neurons in Parkinson's disease.
Hirsch EC; Orieux G; Muriel MP; Francois C; Feger J
Adv Neurol; 2003; 91():29-37. PubMed ID: 12449099
[No Abstract] [Full Text] [Related]
16. Adenosine receptor antagonists and Parkinson's disease: actions of the A2A receptor in the striatum.
Richardson PJ; Gubitz AK; Freeman TC; Dixon AK
Adv Neurol; 1999; 80():111-9. PubMed ID: 10410709
[No Abstract] [Full Text] [Related]
17. Biochemistry of the hypothalamus in Parkinson's disease.
Javoy-Agid F; Ruberg M; Pique L; Bertagna X; Taquet H; Studler JM; Cesselin F; Epelbaum J; Agid Y
Neurology; 1984 May; 34(5):672-5. PubMed ID: 6143285
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptides in Alzheimer's and in Parkinson's disease.
Constantinidis J; Bouras C; Vallet PG
Mt Sinai J Med; 1988 Jan; 55(1):102-15. PubMed ID: 2894608
[No Abstract] [Full Text] [Related]
19. Dopamine and dopamine metabolites in Parkinson's disease-a review.
Barbeau A
Proc Aust Assoc Neurol; 1968; 5(1):95-100. PubMed ID: 4885282
[No Abstract] [Full Text] [Related]
20. The neurochemistry of Parkinson's disease--comments on present and future developments.
Hucho F
J Neural Transm Suppl; 1995; 46():59-65. PubMed ID: 8821041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
